„Our mission is to cure difficult to treat cancers with Innovative Treatment Regimens and Targeted Radionuclide Therapies.

We are a clinical stage company with the aim to leapfrog the treatment of several cancer indications of fast and slow growing cancers for which there are currently only limited therapeutic alternatives.

To accomplish this goal, we use our innovative and tailor-made minigastrin PPF11N which binds with high affinity to the CCK2 receptor.  The CCK2 receptor is expressed on many different cancer types, but virtually not on healthy tissue. We use a theranostic approach which allows us to detect and follow our treatment success via PET imaging. 

Our goal is to increase the long-term survival of eligible cancer patients and simultaneously improve their quality of life with a safe treatment.“